Stopped: Product development cancelled.
The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care. Evaluation will be done with low, medium and then high doses of DS-9231 versus placebo, in participants with medium-risk acute pulmonary embolism.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percent change from baseline in total thrombus volume
Timeframe: Baseline, 48-96 hours after study drug administration
Percentage of participants with various gradations of decrease in total thrombus volume
Timeframe: Baseline, 48-96 hours after study drug administration
Number of participants with major or clinically relevant nonmajor bleeding
Timeframe: within 7 days after study drug administration
Number of participants with adverse events
Timeframe: within 30 days after study drug administration